文献速递脑血管病认知障碍与痴呆

亚临床心脏生物标志物与临床心脏病和皮层微梗死的关联

Association Between Subclinical Cardiac Biomarkers and Clinically Manifest Cardiac Diseases With Cortical Cerebral Microinfarcts.
PubMed 文献 · JAMA Neurol · 2017-01-01

这项记忆门诊的横断面研究纳入243例完成3T MRI和血浆检测的参与者,发现亚临床心脏生物标志物NT-proBNP和hs-cTnT升高及临床心脏病(房颤、缺血性心脏病、心力衰竭)均与皮层微梗死(CMI)相关,且排除临床心脏病后关联仍存在。

要点

  • 亚临床心脏生物标志物NT-proBNP和hs-cTnT升高与皮层微梗死独立相关。
  • 房颤、缺血性心脏病和心力衰竭患者皮层微梗死患病率显著增高。
  • 心脏功能障碍可能是预防皮层微梗死相关脑损伤的可干预靶点。

核心结论

  • 亚临床心脏病生物标志物和临床心脏病均与记忆门诊患者的皮层微梗死相关。
  • 心脏疾病可能促进皮层微梗死的发生,心脏功能障碍应作为可干预因素以预防相关脑损伤。

研究设计与样本

  • 研究为队列研究的基线横断面分析,于2010年8月12日至2015年7月28日进行。
  • 共纳入464例记忆门诊参与者,最终243例纳入分析,平均年龄72.8岁(SD 9.1),男性116例(42.9%)。

主要发现

  • 与无微梗死相比,有微梗死者的房颤率比(RR)为1.62(95%CI 1.20-21.8),缺血性心脏病RR为4.31(95%CI 3.38-5.49),充血性心力衰竭RR为2.05(95%CI 1.29-3.25)。
  • 有微梗死者的NT-proBNP水平显著更高(RR 3.16,95%CI 2.33-4.27),hs-cTnT也更高(RR 2.17,95%CI 1.00-4.74)。
  • 多变量模型调整人口学和血管危险因素后,NT-proBNP较高(RR 3.19,95%CI 2.62-3.90)和hs-cTnT较高(RR 4.86,95%CI 3.03-7.08)与微梗死相关。
  • 排除临床心脏病患者后,上述关联仍然存在。

临床怎么用

  • 在记忆门诊中,检测NT-proBNP和hs-cTnT有助于识别皮层微梗死高风险患者。
  • 对房颤、缺血性心脏病和心力衰竭患者应关注皮层微梗死相关脑损伤风险。
  • 心脏功能障碍可作为预防皮层微梗死相关脑损伤的潜在干预靶点。

局限性

  • 研究为横断面设计,无法确定因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Subclinical and clinical cardiac diseases have been previously linked to magnetic resonance imaging (MRI) manifestations of cerebrovascular disease, such as lacunes and white matter hyperintensities, as well as dementia. Cortical cerebral microinfarcts (CMIs), a novel MRI marker of cerebral vascular disease, have not been studied, to date, in relation to subclinical and clinical cardiac diseases. OBJECTIVE: To examine the association of blood biomarkers of subclinical cardiac disease and clinically manifest cardiac diseases with CMIs graded on 3-T MRI in a memory clinic population. DESIGN, SETTING, AND PARTICIPANTS: This baseline cross-sectional analysis of a cohort study performed from August 12, 2010, to July 28, 2015, included 464 memory clinic participants. All participants underwent collection of blood samples, neuropsychological assessment, and 3-T MRI. EXPOSURES: N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations were measured by electrochemiluminescence immunoassays. Cardiac disease was defined as a history of atrial fibrillation, ischemic heart diseases, or congestive heart failure. MAIN OUTCOMES AND MEASURES: The CMIs were graded according to a previously validated protocol. RESULTS: Of 464 participants, 124 had insufficient blood plasma samples and 97 had no CMI grading (none, incomplete, or ungradable MRI), leaving a sample size of 243 for final analysis (mean [SD] age, 72.8 [9.1] years; 116 men [42.9%]). Seventy participants (28.8%) had cortical CMIs (median, 1; range, 0-43). Compared with participants with no CMIs, those with CMIs had a significantly higher prevalence of atrial fibrillation (rate ratio [RR], 1.62; 95% CI, 1.20-21.8), ischemic heart disease (RR, 4.31; 95% CI, 3.38-5.49), and congestive heart failure (RR, 2.05; 95% CI, 1.29-3.25). Significantly higher levels of NT-proBNP (RR, 3.16; 95% CI, 2.33-4.27) and hs-cTnT (RR, 2.17; 95% CI, 1.00-4.74) were found in participants with CMIs. In multivariate models adjusted for demographics and vascular risk factors, higher levels of NT-proBNP (RR, 3.19; 95% CI, 2.62-3.90) and hs-cTnT (RR, 4.86; 95% CI, 3.03-7.08) were associated with CMIs. These associations persisted even after excluding patients with clinically manifest cardiac disease. CONCLUSIONS AND RELEVANCE: This study found that biomarkers of subclinical cardiac disease and clinically manifest cardiac diseases were associated with CMIs on 3-T MRI in patients attending a memory clinic, suggesting that cardiac disease may contribute to the development of CMIs. Hence, cardiac dysfunction should be targeted as a potentially modifiable factor to prevent CMI-related brain injury.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Hilal S, Chai YL, van Veluw S, et al. Association Between Subclinical Cardiac Biomarkers and Clinically Manifest Cardiac Diseases With Cortical Cerebral Microinfarcts. JAMA Neurol. 2017. PMID: 28166312. doi:10.1001/jamaneurol.2016.5335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。